Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer
BackgroundFor patients with extensive-stage small cell lung cancer (ES-SCLC), serplulimab plus chemotherapy is beneficial as the first-line treatment. It is uncertain whether serplulimab plus chemotherapy will be more cost-effective. The aim of this study was to evaluate from the perspective of the...
Tallennettuna:
Päätekijät: | , , , |
---|---|
Aineistotyyppi: | Kirja |
Julkaistu: |
Frontiers Media S.A.,
2023-08-01T00:00:00Z.
|
Aiheet: | |
Linkit: | Connect to this object online. |
Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|
Internet
Connect to this object online.3rd Floor Main Library
Hyllypaikka: |
A1234.567 |
---|---|
Nide 1 | Saatavissa |